Safety and Efficacy Study of Association Between Tretinoin and Clindamycin on the Treatment of Acne Mild and Moderate
Monocentric Study, Prospective, Open and Non Controlled for to Evaluate the Effectiveness, and Tolerability the Safety of Association of Clindamycin Phosphate 1.2% and Tretinoin 0,025% in the Treatment of Acne Vulgaris Mild to Moderate, When Used Once Daily for 12 Weeks.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil, 13276-245
- LAL Clínica
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals of both sexes with age greater than or equal to 12 years
Subjects diagnosed with acne vulgaris in the face, except for the nasal area, range from mild to moderate, with the following requirements.
- Mild acne = presence of fewer than 20 comedones or less than 15 lesions, inflammatory lesions or a total of less than 30 injuries.
- Moderate acne = presence of 20 the 100 comedones or of 15 the 50 inflamatory lesions or a total of 30 the 125 lesions, with not more than lesions small nodule until 5,0 mm.
- Ensure that the existing injuries were not submitted any treatment for acne, topical or systemic, within the last 30 days.
- Be able to properly follow the determinations of the Protocol.
- Has provided a written voluntary consent to participate in the study, by signing the informed consent, before being subjected to any procedure.
- Under 18 years old, be accompanied by legal guardian in the process of obtaining the informed consent.
- Be mentally able to provide consent and be fulfilling all the requirements of the study.
Exclusion Criteria:
- Pregnant women or in periods of lactation.
- Women of childbearing age and sexual activity with not using safe contraceptive method, such as oral contraceptives, implantable, injectable or intra-uterine, introduced for at least 120 days.
- Women who are using oral contraceptives containing the hormone combination for acetate ciprosterone and etinolestradiol, association of drospirenone and ethinyl estradiol, or desogestrel.
- Clinical evidence or history of immunodeficiency.
- Any use of immunosuppressive drug and/or immunomodulating over the past 3 months, topical or systemic.
- Concurrent use of fotossentetizadores, neuromuscular blockers, medications that exacerbate the acne, blockers (filters) with solar alcoholic vehicle, spironolactone, flutamide or zinc salts.
- Prior use of systemic retinoid.
- Presence of acne medication and/or cosmetic.
- History of systemic metabolic disorder that can interfere with the integrity of the skin.
- History of inflammatory disease, intestinal or regional enteritis and/or symptoms similar.
- History of joy to any of the components of the formula (active principle or carrier).
- History of abuse of alcohol and/or illegal drugs.
- History of non-adherence to medical treatment earlier.
- Any clinical observation made by the investigator that prohibits participation in the study of the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: clindamicin and tretinoin gel
|
Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluation of the efficacy, through number of lesions, and tolerability of the product.
Time Frame: three months
|
three months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IGF 03-42008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.